What is TMS and where does the evidence show it works?
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation technique that uses magnetic pulses to modulate neural activity. It is already approved in many countries for conditions like depression and migraine [4]. The strongest evidence from these papers supports its use for depression—both unipolar and bipolar. A 2025 meta-analysis found that active TMS produced a moderate antidepressant effect in bipolar depression (standardized mean difference 0.4–0.6), comparable to standard antidepressants, with no increased risk of manic switching [2]. This challenges older concerns that TMS might trigger mania in bipolar patients.
TMS also shows promise for other conditions, though the evidence is less mature. For chemotherapy-related cognitive impairment ('chemo brain'), a pilot study of one patient reported significant memory improvement after 10 sessions, plus a promotion at work after 5–6 months [4]. For disorders of consciousness, TMS most consistently improves consciousness scores in minimally conscious state patients, but evidence is weak for vegetative state and absent for coma [3]. These applications are promising but not yet ready for routine clinical use.
The main barrier: clinician knowledge, not the technology
The biggest obstacle to TMS becoming a public health tool is not a lack of efficacy but a lack of awareness and training among doctors. A 2022 survey of nearly 2,000 Norwegian psychiatrists found that 49% were unfamiliar with TMS, and 84% said insufficient training of doctors limited its use [1]. Yet 82% expressed a desire to learn more, and 80% called for national clinical guidelines [1]. This suggests that TMS is clinically ready but not yet integrated into medical education or practice.
This knowledge gap matters because TMS response varies between patients, and doctors need tools to predict who will benefit. A 2023 study using machine learning on brain scans (fMRI) achieved 94% accuracy in predicting which depressed patients would respond to TMS, identifying specific brain connectivity patterns as biomarkers [5]. Another review highlighted that TMS combined with EEG can measure brain circuit function and may eventually guide treatment choices, but this is still in early validation stages [6]. So while the treatment itself works, the healthcare system needs better training and predictive tools to deploy it effectively.
Where the evidence conflicts or falls short
The studies agree that TMS is effective for depression, but they conflict on how ready it is for broader use. The survey [1] emphasizes that doctors lack knowledge, implying the therapy is underused despite being ready. In contrast, the biomarker studies [5][6] suggest that without better patient selection tools, TMS will remain inefficient—some patients will get no benefit, wasting resources. This is not a true contradiction: TMS works on average, but individual response is variable, and the field is still identifying who responds best.
Another gap is the uneven evidence across conditions. For depression, large meta-analyses exist [2]. For chemo brain, only a single-patient pilot study is available [4]. For disorders of consciousness, evidence is strongest for minimally conscious patients but weak for others [3]. So TMS is clinically ready for depression, but for other uses it remains experimental. The papers also note that most TMS research has been on unipolar depression, and direct comparisons with medication are rare [2].
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2023 to 2026, 3 from 2024 or later, 4 in Q1 journals, collectively cited 55 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 71 papers retrieved from a database of over 500 million.
Sources used in this answer
Transcranial magnetic stimulation in mental health care
A 2022 survey of 481 Norwegian psychiatrists found 49% were unfamiliar with TMS, 84% cited insufficient training as a barrier, and 80% wanted national guidelines—showing clinician knowledge, not efficacy, is the main obstacle to wider use.
Bridging the Poles: What the Transcranial Magnetic Stimulation Evidence Tells Us About Bipolar Depression
A 2025 meta-analysis of TMS for bipolar depression found a moderate antidepressant effect (standardized mean difference 0.4–0.6) comparable to medication, with no increased risk of mania—supporting broader clinical use.
State-dependent repetitive transcranial magnetic stimulation in disorders of consciousness
A narrative review of TMS for disorders of consciousness found the strongest evidence for improving consciousness in minimally conscious state patients, but weak evidence for vegetative state and no evidence for coma—indicating limited readiness for these populations.
Transcranial Magnetic Stimulation for the Treatment of Chemo Brain
A pilot study of one patient with chemotherapy-related cognitive impairment ('chemo brain') found that 10 TMS sessions improved memory on neuropsychological tests and led to a job promotion 5–6 months later—promising but very preliminary.
Identifying predictive biomarkers for repetitive transcranial magnetic stimulation response in depression patients with explainability
A machine learning study using fMRI brain scans achieved 94% accuracy in predicting which depressed patients would respond to TMS, identifying specific brain connectivity patterns as biomarkers—suggesting readiness for predictive tools.
Transcranial Magnetic Stimulation–Electroencephalography for Biomarker Discovery in Psychiatry
A review of TMS-EEG for biomarker discovery in psychiatry concluded that while predictors of TMS response show promise, the approach is still in early validation stages and not yet ready for clinical implementation.